CHU de Toulouse - Hôpital Pierre-Paul Riquet

The department is investigating Coronary Artery Disease through a study that compares the performance of an angiolite stent with a standard‑of‑care device, while also evaluating dual antiplatelet therapy strategies to reduce bleeding risks.

• Stent performance comparison
• Bleeding risk assessment
• Long‑term disease‑free survival

Researchers at CHU de Toulouse — Hôpital Pierre‑Paul Riquet are contributing to national guidelines on cardiovascular device safety and therapy optimization.

Clinical work focuses on Crohn's Disease and various gastrointestinal cancers, including colon cancer, pancreatic ductal adenocarcinoma, and liver‑metastatic colorectal disease, to refine chemotherapy delivery and improve remission rates.

• Intra‑arterial chemotherapy delivery
• Adjuvant oxaliplatin regimens
• Transmural healing in Crohn's disease
• Metastatic colorectal liver disease management

The site’s multidisciplinary team collaborates with surgical and radiology units to accelerate therapeutic advances for digestive disorders.

While current trial activity is limited in this area, the center maintains expertise in female urogenital health and is prepared to support future investigations on hormonal balance, pregnancy outcomes, and pelvic conditions.

• Hormonal regulation studies
• Pregnancy outcome monitoring
• Urogenital infection research
• Pelvic health assessments

Ongoing collaboration with obstetrics and gynecology partners ensures rapid initiation of new studies when opportunities arise.

A key investigation targets Type 1 Diabetes, testing the immune‑modulating agent baricitinib to delay progression to stage 3 disease in at‑risk individuals.

• Immune‑modulating drug evaluation
• Prevention of disease progression
• Biomarker development for autoimmune risk
• Safety profiling in at‑risk populations

The research contributes to broader efforts to intervene early in autoimmune conditions and improve long‑term outcomes.

Studies address prostatic adenocarcinoma and non‑muscle invasive bladder cancer, evaluating adjuvant hormonal therapy with leuprorelin acetate after prostatectomy and gene‑therapy approaches such as nadofaragene firadenovec for bladder cancer recurrence prevention.

• Adjuvant hormonal therapy after prostatectomy
• Gene‑therapy approaches for bladder cancer
• Recurrence risk reduction strategies
• Long‑term survival monitoring

Collaboration with the urology department enables comprehensive care pathways for male urogenital malignancies.

The site conducts extensive oncology research across a spectrum of neoplasms, including trials for hepatocellular carcinoma, metastatic colorectal cancer, and high‑risk colon cancer, aiming to test new drug combinations and improve overall survival.

• Combination chemotherapy trials
• Targeted therapy assessment
• Survival outcome analyses
• Metastasis prevention studies

CHU de Toulouse — Hôpital Pierre‑Paul Riquet remains a pivotal hub for advancing cancer treatment protocols in Europe.